Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation

Area of Science:

• Oncology
• Clinical Trials
• Breast Cancer Research

Background:

• The post-neoadjuvant setting for early breast cancer (BC) patients with residual disease (RD) after primary treatment is a critical unmet need.
• Limited standard therapies exist for managing high-risk BC patients who do not achieve pathologic complete response (pCR).
• Current guidelines suggest considering capecitabine for specific subtypes, highlighting the need for further research.

Purpose of the Study:

• To review emerging therapeutic options and ongoing clinical trials for early BC patients with RD post-neoadjuvant therapy.
• To emphasize the importance of prognostic and predictive biomarkers for risk stratification and treatment selection.
• To discuss the challenges and future directions in managing this patient population.

Main Methods:

• Literature review of clinical trials and studies in the post-neoadjuvant setting for early breast cancer.
• Analysis of current treatment strategies and emerging therapeutic agents.
• Focus on biomarker research for patient selection and risk assessment.

Main Results:

• Several novel agents, including platinum salts, PARP inhibitors, and immune checkpoint inhibitors, are under investigation.
• Capecitabine has shown benefit in a phase III trial and is recommended for consideration, especially in triple-negative BC.
• Biomarker validation is essential for identifying patients likely to benefit from post-neoadjuvant interventions.

Conclusions:

• The post-neoadjuvant setting presents a vital opportunity for clinical trials in high-risk early breast cancer.
• Effective risk stratification using biomarkers is paramount for optimizing treatment selection.
• Continued research into novel therapies and biomarkers is necessary to improve outcomes for patients with residual disease.